Samuel Kintz - Feb 26, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Feb 26, 2024
Transactions value $
-$189,213
Form type
4
Date filed
2/28/2024, 05:14 PM
Previous filing
Feb 15, 2024
Next filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $13.4K +12K $1.12* 12K Feb 26, 2024 Direct F1
transaction ELVN Common Stock Sale -$127K -7.62K -63.53% $16.69 4.38K Feb 26, 2024 Direct F1, F2
transaction ELVN Common Stock Sale -$75.4K -4.38K -100% $17.24 0 Feb 26, 2024 Direct F1, F3
holding ELVN Common Stock 1.09M Feb 26, 2024 See footnote F4
holding ELVN Common Stock 88.5K Feb 26, 2024 See footnote F5
holding ELVN Common Stock 88.5K Feb 26, 2024 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -12K -4.22% $0.00 273K Feb 26, 2024 Common Stock 12K $1.12 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $16.00 to $16.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $17.00 to $17.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
F5 The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's elder son and for which the Reporting Person serves as an investment advisor.
F6 The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's younger son and for which the Reporting Person serves as an investment advisor.
F7 The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.